Legend Biotech (NASDAQ:LEGN) received 4 analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, and 1 indifferent. The 12-month price targets from these analysts average $82.75, with a high of $93.00 and a low of $65.00. The current average shows a 5.61% decline from the prior average. Legend Biotech is a clinical-stage biopharmaceutical company with a lead CAR T cell therapy product for multiple myeloma. The company has shown a revenue growth rate of 250.91% as of September 30, 2023, but faces challenges with a net margin of -64.79%, ROE of -4.53%, and ROA of -3.3%. Its debt-to-equity ratio is 0.24, below industry norms.